Nonalcoholic fatty liver disease: Synopsis of current developments

被引:24
|
作者
Onyekwere, C. A. [1 ]
Ogbera, A. O. [1 ]
Samaila, A. A. [4 ]
Balogun, B. O. [2 ]
Abdulkareem, F. B. [3 ]
机构
[1] Lagos State Univ, Teaching Hosp, Coll Med, Dept Med, Lagos, Nigeria
[2] Lagos State Univ, Teaching Hosp, Coll Med, Dept Radiol, Lagos, Nigeria
[3] Univ Lagos, Teaching Hosp, Coll Med, Dept Anat & Mol Pathol, Lagos, Nigeria
[4] Bayero Univ, Aminu Kano Teaching Hosp, Dept Med, Gastroenterol Unit, Kano, Nigeria
关键词
Current development; nonalcoholic fatty liver disease; review; synopsis; update; INSULIN-RESISTANCE; HEPATIC STEATOSIS; DIAGNOSTIC-VALUE; RISK-FACTORS; ASSOCIATION; POPULATION; NAFLD; STEATOHEPATITIS; PATHOGENESIS; PATHOLOGY;
D O I
10.4103/1119-3077.163288
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Non-alcoholic fatty liver disease (NAFLD) which is defined as the accumulation of fat > 5% of liver weight is increasingly becoming an important cause of chronic liver disease. This article tries to chronicle advances that have occurred in the understanding of the pathogenesis, pathology as well as the management of this disease. We have done a Medline search on published work on the subject and reviewed major conference proceedings in the preceding years. The Pathogenesis involves a multi-hit process in which increased accumulation of triglycerides in face of insulin resistance results in increased susceptibility to inflammatory damage mediated by increased expression of inflammatory cytokines and adipokines, oxidative stress and mitochondrial dysfunction, endoplasmic reticulum stress and gut derived endotoxemia. An interplay of multiple metabolic genetic expression and environmental factors however determine which patient with NAFLD will progress from simple steatosis to non-alcoholic steatohepatitis (NASH) and liver cirrhosis. The minimum criteria for diagnosis of NASH are steatosis, ballooning and lobular inflammation; fibrosis is not required. The NASH Clinical Research Network (CRN), histological scoring system is used to grade and stage the disease for standardization. The management of NAFLD consists of treating liver disease as well as associated metabolic co-morbidities such as obesity, hyperlipidaemia, insulin resistance and type 2 diabetes mellitus (T2DM). Patient education is important as their insight and commitment is pivotal, and lifestyle modification is the first line of treatment. Improvement in liver histology in non-diabetic NASH patients has been reported with use of Vitamin E. Other liver-related therapies under investigations include pentoxyfiylins, Caspar inhibitors, Resveratrol as well as probiotics. The prognosis (both overall and liver-related mortality) for simple steatosis is not different from that of the general population however.
引用
收藏
页码:703 / 712
页数:10
相关论文
共 50 条
  • [1] Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments
    Ahn, Sang Bong
    [J]. CLINICAL AND MOLECULAR HEPATOLOGY, 2023, 29 : S150 - S156
  • [2] Current treatment for nonalcoholic fatty liver disease
    Katsiki, Niki
    Athyros, Vasilios G.
    Karagiannis, Asterios
    Mikhailidis, Dimitri P.
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (13) : 2141 - 2142
  • [3] Current Treatment of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
    Hung, Chun Kit
    Bodenheimer, Henry C., Jr.
    [J]. CLINICS IN LIVER DISEASE, 2018, 22 (01) : 175 - +
  • [4] Nonalcoholic Fatty Liver Disease: Current Concepts
    Tziomalos, Konstantinos
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2018, 24 (38) : 4564 - 4565
  • [5] CURRENT THERAPIES FOR NONALCOHOLIC FATTY LIVER DISEASE
    Gossard, A. A.
    Lindor, K. D.
    [J]. DRUGS OF TODAY, 2011, 47 (12) : 915 - 922
  • [6] Overview and developments in noninvasive diagnosis of nonalcoholic fatty liver disease
    Barsic, Neven
    Lerotic, Ivan
    Smircic-Duvnjak, Lea
    Tomasic, Vedran
    Duvnjak, Marko
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2012, 18 (30) : 3945 - 3954
  • [7] Overview and developments in noninvasive diagnosis of nonalcoholic fatty liver disease
    Neven Bari
    Ivan Leroti
    Lea Smiri-Duvnjak
    Vedran Tomai
    Marko Duvnjak
    [J]. World Journal of Gastroenterology, 2012, (30) : 3945 - 3954
  • [8] Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
    Yoshihisa Takahashi
    Keiichiro Sugimoto
    Hiroshi Inui
    Toshio Fukusato
    [J]. World Journal of Gastroenterology, 2015, 21 (13) : 3777 - 3785
  • [9] Current treatment options for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
    Beaton, Melanie D.
    [J]. CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2012, 26 (06) : 353 - 357
  • [10] Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
    Takahashi, Yoshihisa
    Sugimoto, Keiichiro
    Inui, Hiroshi
    Fukusato, Toshio
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2015, 21 (13) : 3777 - 3785